Chinese Academy of Medical Sciences Dermatology Hospital

This trial is a phase II exploratory clinical trial, which aims to explore the effectiveness and safety of different formulations of tazacycline cream in the treatment of moderate acne vulgaris, and preliminarily determine the optimal formulation group to provide a theoretical basis for the design of the phase III clinical trial program.

Tazarotene cream (10 g/tube, containing 0.05% tazarotene and 1% clindamycin) was used as the test preparation, and 0.1% tazarotene cream (Levitra®) and clindamycin phosphate gel (Darlin®) were used as control preparations. The skin reactions at the administration site, safety indicators, and drug exposure in the body after percutaneous absorption after a single topical administration of the test preparation or a single control preparation were investigated in healthy subjects, so as to evaluate the safety of tazarotene cream and its tolerability at a given dose.

Tazarotene cream (10 g/tube, containing 0.05% tazarotene and 1% clindamycin) was used as the test preparation, and 0.1% tazarotene cream (Lewei®) and clindamycin phosphate gel (Darlin®) were used as control preparations. The skin reactions at the administration site, safety indicators, and drug exposure in the body after percutaneous absorption were investigated in healthy subjects after a single topical administration of the test preparation or a single control preparation, so as to evaluate the safety of tazarotene cream and its tolerability at a given dose.